ROANOKE, Va. (WDBJ) - For patients needing cataract surgery, the new Light Adjustable Lens could be a game changer when it comes to fine tuning eyesight after surgery. It’s the first and only ...
A federal appellate court has upheld the Drug Enforcement Administration’s denial of a Seattle doctor’s request to use ...
The Federal Drug Administration last month approved Journavx, a new kind of non-addictive pain medication. Doctors say ...
Received overwhelming shareholder support in favour of take-private transaction with AditxtAdvanced key pipeline programs, engaged regulatory ...
According to the FDA, the medication quickly helps to lower mealtime blood sugar spikes to improve control of blood sugar in ...
A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives ...
The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...
The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...
Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...
• The Give Kids a Chance Act – Reinstates the rare pediatric priority review voucher program, also known as the Creating Hope ...
The US Food and Drug Administration has approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC) to treat adult ...
Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.